poisar

Stocks · News reference

Micron To Rally Around 187%? Here Are 10 Top Analyst Forecasts For Wednesday

Avi Kapoor

Wall Street analysts revised targets: upgrades for NetApp and Humana; downgrades for PJT Partners; mixed target changes for Redwood, Marvell, Yum and S&P

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ABTCBHUMMRVLMUNTAPPJTRWTSPGIYUMZS
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Researchandmarkets.Com

    Global Sacral Neuromodulation Market Size, Share, Trends and Forecast 2026-2036: Rechargeable, MRI-Compatible Systems Drive 11.1% CAGR

    The global sacral neuromodulation market is estimated at USD 1.37 billion in 2026 and projected to reach USD 3.92 billion by 2036, growing at 11.1% CAGR. Market expansion is driven by rising prevalence of urinary and fecal incontinence, aging populations, and technological advancements in rechargeable and MRI-compatible devices. Key challenges include high procedural costs and complex regulatory requirements. North America leads the market while Asia-Pacific is expected to register the fastest growth.

    MDTBSXABTLIVN
  5. Harsh Chauhan

    Sandisk Is Splitting Its Stock 8-for-1. Is Micron Technology Next?

    Sandisk announced an 8-for-1 stock split effective November 20, 2026, to make shares more accessible to retail investors following strong Q1 fiscal 2027 results. The article speculates that Micron Technology may follow suit when it reports December results, as both memory chip manufacturers have seen significant stock appreciation driven by AI-fueled demand for DRAM and NAND flash storage.

    SNDKMU
  6. Bbb National Programs

    National Advertising Division to Refer Kendal to Government Agencies and Advertising Platforms for Electing Not to Participate in Compliance Inquiry

    The National Advertising Division (NAD) of BBB National Programs will refer Kendal Nutricare Limited to government agencies and advertising platforms for enforcement action after the company refused to participate in a compliance inquiry. This follows a challenge by Abbott Laboratories regarding Kendamil Infant Formula advertising claims about whole milk, breast milk, HMOs, and milk fat content that NAD had previously recommended be discontinued or modified.

    ABT